Company Overview & Pipeline
Unicycive Therapeutics specializes in therapies for kidney-related disorders. Its lead candidate, Oxylanthanum Carbonate (OLC), is an investigational oral phosphate binder for patients with end-stage renal disease on dialysis who suffer from hyperphosphatemia (elevated phosphate levels) (ir.unicycive.com) (ir.unicycive.com). OLC leverages a proprietary nanoparticle formulation to achieve high phosphate-binding potency, which significantly lowers the pill burden for patients (ir.unicycive.com). This could be a breakthrough in a space where current phosphate binders require patients to swallow many large pills with each meal. Unicycive is seeking FDA approval of OLC via the streamlined 505(b)(2) pathway, and notably the FDA did not identify any clinical efficacy or safety concerns in the original review – the only issue was manufacturing, which we discuss later (ir.unicycive.com).
Beyond OLC, Unicycive’s pipeline includes UNI-494, a compound in development for acute kidney injury and related conditions (ir.unicycive.com). UNI-494 has received FDA Orphan Drug designation for preventing delayed graft function in kidney transplant patients (ir.unicycive.com), and a Phase 1 safety study in healthy volunteers has been completed. This second program is earlier-stage, and near-term the company’s fortunes rest primarily on OLC’s approval and commercialization. Unicycive has also pursued partnerships to extend its reach – for example, it licensed OLC to Lee’s Pharmaceutical for development and commercialization in China and certain Asian markets (edgar.secdatabase.com). Under that agreement Lee’s Pharma will handle local trials and regulatory filings, which could eventually generate milestone or royalty revenues for Unicycive if OLC is approved abroad (edgar.secdatabase.com). In sum, UNCY is positioning OLC as a potential new standard for phosphate control in dialysis patients, with a secondary asset (UNI-494) providing longer-term optionality in its pipeline.
FDA Resubmission Accepted – Latest Developments
The big catalyst for UNCY is the FDA’s acceptance of the OLC NDA resubmission announced on January 29, 2026. This resubmission came after Unicycive had received a Complete Response Letter (CRL) in June 2025, which cited a compliance deficiency at a third-party manufacturing vendor as the sole issue preventing approval (ir.unicycive.com). Importantly, no problems were found with OLC’s clinical, preclinical, or safety data in that CRL (ir.unicycive.com). Unicycive engaged in a Type A meeting with the FDA in late 2025 to clarify the path forward, and the FDA confirmed that resolving the single manufacturing issue could clear the way for approval (ir.unicycive.com). Following this guidance, the company worked with the contract manufacturer to address the deficiencies, even noting that a European regulator’s inspection of the facility found no outstanding issues (ir.unicycive.com). Unicycive resubmitted the NDA in late December 2025 (ir.unicycive.com).
With the FDA’s recent acceptance, the review clock is officially ticking. The NDA resubmission is classified for a 6-month review, giving a PDUFA (Prescription Drug User Fee Act) target date of June 27, 2026 (ir.unicycive.com). In the acceptance announcement, CEO Dr. Shalabh Gupta expressed confidence and indicated the team is gearing up for commercialization: “We are pleased that the agency has promptly accepted the resubmission… We are advancing our commercial preparation activities in anticipation of a potential launch of OLC later this year” (ir.unicycive.com). This suggests Unicycive is already making plans for marketing, distribution, and patient access so that, if approval comes mid-2026, the drug could reach patients quickly thereafter.
It’s worth noting what data supports OLC’s NDA. Because OLC is being reviewed via the 505(b)(2) pathway, Unicycive was able to reference existing data on previously approved phosphate binders, supplemented by its own studies. The NDA includes results from three clinical studies (a Phase 1 trial in healthy volunteers, a bioequivalence study, and a tolerability study in dialysis patients), multiple preclinical studies, and comprehensive chemistry/manufacturing/control (CMC) information (ir.unicycive.com). Crucially, the FDA did not flag any efficacy or safety shortcomings in these data (ir.unicycive.com) – the earlier delay was solely about manufacturing compliance. This de-risks the pending review to some extent, as the primary hurdle (manufacturing) appears to have been addressed. However, investors will be watching for FDA’s final inspection of the manufacturing site and any remaining questions during the review.
In parallel, the market landscape for hyperphosphatemia treatments is evolving. In October 2023, Ardelyx received FDA approval for Xphozah (tenapanor), a first-in-class phosphate absorption inhibitor (www.biopharmadive.com). Xphozah is approved as an add-on therapy for dialysis patients who don’t respond well to phosphate binders (www.biopharmadive.com). This was the first new hyperphosphatemia drug in many years, and Ardelyx launched Xphozah in late 2023 with a dedicated U.S. sales force (www.biopharmadive.com). While Xphozah works via a different mechanism (reducing phosphate absorption in the gut) and is indicated for patients with inadequate control on binders, its entry highlights both the unmet need and growing competition in this space. Traditional binder drugs like sevelamer carbonate (Renvela, now generic), lanthanum carbonate (Fosrenol), and others have dominated care for decades. The selling point for OLC will be its lower pill burden and patient-friendly profile (ir.unicycive.com) – a contrast to sevelamer or calcium-based binders that often require large, frequent doses. The hyperphosphatemia drug market is substantial, estimated at ~$2.8 billion in 2025 and projected to approach ~$3.8 billion by 2030 (www.mordorintelligence.com), as the dialysis population grows and novel therapies (like tenapanor, and potentially OLC) gain traction. This backdrop means that if OLC wins approval, Unicycive could tap into a multi-billion market – but it will also face the challenge of competing against entrenched generics and persuading doctors/insurers of OLC’s benefits.
Dividend Policy & Shareholder Returns
Unicycive is not a dividend-paying company currently, which is typical for a pre-revenue biotech focused on growth. The company has never paid a common stock dividend to date and had planned to retain any future earnings to fund development (edgar.secdatabase.com). However, in a unique twist, Unicycive modified its dividend policy in March 2023 as part of a financing agreement. The company agreed that if OLC is approved by the FDA and commercial sales commence, it intends to pay quarterly dividends totaling at least 75% of annual net cash flow from operations (edgar.secdatabase.com). In other words, once OLC is on the market and generating cash, Unicycive has pledged to return the majority of those operating cash flows to shareholders as dividends. This unusual commitment – essentially a promise of a high payout ratio upon successful commercialization – was likely a concession to investors in that 2023 capital raise.
For now, any dividend is hypothetical and contingent on OLC reaching the market and throwing off cash. If OLC does become a profitable product, a 75% cash flow payout could translate into significant future yield for shareholders. But investors should keep in mind that this policy could be revisited by the board, and high payouts might also limit the cash available for re-investment in R&D or new opportunities. In the meantime, with no current earnings or free cash flow (FFO/AFFO) to speak of, there is no dividend yield at present. All of Unicycive’s value proposition is centered on capital appreciation from successful drug development rather than income. The promise of potential dividends underscores management’s confidence in OLC’s cash-generating prospects, but it remains a long-term prospect dependent on execution. For now, returns to shareholders will come from stock price movement, not distributions.
Cash Position, Leverage & Debt Maturities
Biotechs like UNCY live or die by their cash runway, and Unicycive appears to be on solid footing in the near term. The company ended 2025 with $41.3 million in cash, cash equivalents, and short-term investments (unaudited) (ir.unicycive.com). This was bolstered by substantial fundraising in 2023–2024, and management indicates this war chest is sufficient to fund operations into 2027 (ir.unicycive.com) (ir.unicycive.com). In fact, after a major financing in March 2024, Unicycive has stated it has the capital to carry through the regulatory approval process and even support initial commercialization activities for OLC (ir.unicycive.com). Having runway into 2027 suggests that – barring unforeseen expenses – the company should not need to raise additional capital before the anticipated mid-2026 approval decision and initial launch. This is a critical advantage; it reduces the risk of dilutive stock offerings in the interim and allows management to focus on execution.
In terms of leverage, Unicycive carries essentially no traditional debt on its balance sheet. The September 30, 2025 balance sheet shows no short- or long-term loans – liabilities consisted mainly of accounts payable, lease obligations, and a sizable warrant liability (related to outstanding warrants from recent financings) (www.sec.gov). Interest expense was negligible ($44,000 in the first nine months of 2025) and was more than offset by interest income earned on the company’s cash holdings (www.sec.gov). This minimal debt load means no looming debt maturities or interest burdens threaten the company in the near term. The flip side is that operations are being funded by equity capital, which, as discussed below, has led to significant share dilution.
One item to note is the warrant and preferred stock structures from recent financings. In March 2023 and March 2024, Unicycive raised cash through private placements of preferred shares with attached warrants (edgar.secdatabase.com). These instruments (Series A and B preferred, and Tranche A/B/C warrants) have complex terms, but importantly they provide contingent funding in the future. For example, a Tranche A warrant gives investors the right to purchase additional preferred shares for an aggregate $25 million exercise price, exercisable within a short window after FDA approval of OLC (edgar.secdatabase.com) (edgar.secdatabase.com). If OLC is approved, exercising these warrants would bring in new cash (helpful for commercialization) but also dilute existing shareholders by issuing a large number of new shares (the Series A-3 preferred from Tranche A is ultimately convertible into tens of millions of common shares) (edgar.secdatabase.com) (edgar.secdatabase.com). Similar structures (Tranche B, C) could trigger further funding/dilution upon future milestones. The net effect is that Unicycive’s true leverage is via equity dilution rather than debt – past investors have capitalized the company in return for a sizeable stake, and future dilution is possible if milestone-based warrants are exercised. Investors should be aware that as of November 2025 the company had ~21.5 million common shares outstanding (www.sec.gov) (after a 1-for-10 reverse split in 2025), but this share count could increase substantially if all pref shares and warrants eventually convert.
From a credit perspective, Unicycive’s balance sheet is relatively clean. There are no significant loan maturities or mandatory payments coming due that could pressure cash flow. The only fixed financial obligations are standard operating lease payments for its facilities (the lease liability was very small by Q3 2025) (www.sec.gov). Thus, coverage ratios like interest coverage or debt service coverage are not meaningful – the company’s interest burden is near-zero, and it relies on equity capital to cover its operating cash burn. The main coverage consideration is how long the cash on hand can cover the company’s operating losses. In the first nine months of 2025, Unicycive’s operating cash burn (net loss adjusted for non-cash items) was on the order of ~$12 million (www.sec.gov), reflecting scaled-back R&D spending post-CRL. At that burn rate, $41 million could last roughly 2–3 years, aligning with management’s guidance of runway into 2027. Of course, expenses will ramp up if OLC is approved and a salesforce and inventory are needed – but presumably, initial commercial outlays could be financed by that future warrant exercise or by early revenues. Overall, Unicycive’s financial position shows low leverage and a healthy cash buffer, which reduces near-term financial risk as the company navigates the FDA review and (hopefully) transitions to commercialization.
Valuation and Comparables
Unicycive remains a micro-cap biotech, reflecting both the early stage of its business (no product revenue yet) and the risks still ahead. As of late January 2026, UNCY’s stock trades in the mid-$3 range, which equates to a market capitalization around $80–90 million (with ~21.5 million shares out). Backing out the ~$41 million in cash on the balance sheet, the enterprise value (EV) is on the order of $40–50 million. This modest EV reflects that the market is valuing the company only slightly above its cash – implying skepticism or caution around the unproven asset OLC. In other words, investors today are paying a little extra (beyond cash) for the option value that OLC wins approval and becomes a commercial success.
How does this valuation stack up? One way to gauge it is relative to the potential market opportunity. The U.S. alone has over 450,000 dialysis patients who require medication to control phosphate levels (ir.unicycive.com). The total global market for hyperphosphatemia drugs is estimated near $3 billion annually (www.mordorintelligence.com). If OLC secures FDA approval and can penetrate even a modest slice of this market, the annual revenue potential could be in the hundreds of millions of dollars. For instance, achieving just 10% of the U.S. dialysis population (~45,000 patients) on OLC at a couple of thousand dollars per patient per year would imply ~$90+ million in revenue. Higher pricing or international expansion could increase that. By that yardstick, an enterprise value of ~$50 million appears low – suggesting significant upside if OLC’s launch goes well.
Another comparison is to peers. Competitor Ardelyx (ARDX), which launched Xphozah, provides a reference point. Ardelyx, after securing FDA approval in 2023, quickly grew its market cap into the several-hundred-million range and reported over $97 million in quarterly revenue by Q2 2025 (from Xphozah and other products) (ir.ardelyx.com). While Ardelyx has multiple products (including an IBS drug) and a first-mover advantage with Xphozah, the contrast shows how valuation can expand dramatically as a biotech transitions to a revenue-generating commercial stage. In phosphate binders, historical benchmarks like Sanofi’s Renvela (sevelamer) once achieved blockbuster sales globally before generics, indicating the revenue potential for an effective therapy. That said, Unicycive’s current valuation also prices in the execution risks – a small company launching its first product against generic incumbents is no sure thing.
Traditional valuation metrics like P/E or P/FFO are not applicable yet, since Unicycive has no earnings (net losses) and negative funds from operations. The price-to-book ratio can be calculated: with ~$37.5 million in shareholders’ equity at Q3 2025 (www.sec.gov) and a market cap around $85 million, UNCY trades at roughly 2.3× book value – not unusual for a biotech with a key asset in late-stage review. In summary, Unicycive’s valuation is reasonable relative to its cash and stage, but it arguably does not yet reflect full credit for OLC’s potential. This likely represents a “risk discount” that will persist until FDA approval is more certain and investors see evidence of market uptake. If OLC gets approved on schedule and Unicycive executes a competent launch, there's room for the valuation to re-rate higher. Conversely, any setbacks (regulatory or commercial) could leave the stock price vulnerable, given that a single asset underpins most of the valuation.
Key Risks and Red Flags
Despite the encouraging NDA progress, UNCY comes with significant risks inherent to small biotech investments. Here are the key risks and red flags to consider:
- Regulatory Approval Risk: OLC is not approved yet – the FDA review is ongoing. The approval process is inherently unpredictable and lengthy (edgar.secdatabase.com), and a negative outcome on the June 2026 PDUFA date would be devastating for the stock. While the manufacturing issue is reportedly resolved, there is always a chance the FDA finds new issues or delays (e.g. if re-inspection of the plant takes longer). If approval is not obtained, Unicycive as a company would be severely harmed (edgar.secdatabase.com), having no product revenue and having expended its cash on the effort.
- Commercial and Execution Risk: Even if OLC is approved, market acceptance is not guaranteed. Physicians, dialysis centers, and payors may stick with existing phosphate binders (many of which are generic and inexpensive) unless OLC demonstrably improves patient outcomes or adherence. The company acknowledges that a product may fail to achieve the degree of market acceptance necessary for commercial success (edgar.secdatabase.com). It will also face pricing and reimbursement challenges – insurers could be hesitant to reimburse a premium-priced new binder and might restrict OLC use via prior authorizations or only for patients who fail generics (edgar.secdatabase.com). Unicycive’s lack of prior commercial experience is a concern: this will be its first drug launch, and building a sales infrastructure from scratch is challenging. Execution missteps in manufacturing supply, marketing to nephrologists, or patient support could impede uptake. Additionally, Ardelyx’s Xphozah – though an adjunct therapy – will compete for the mindshare (and budgets) of dialysis providers, potentially making OLC’s uptake slower if used in combination with, rather than instead of, binders.
- Financial and Dilution Risk: Unicycive’s operations will likely continue to lose money for some time, even after a product launch. The company will need to spend on sales, marketing, and post-approval studies, all while its R&D pipeline (like UNI-494) may demand funding. If OLC’s revenue ramp is slow or below expectations, Unicycive may need to raise additional capital, which could be dilutive to shareholders (edgar.secdatabase.com) (edgar.secdatabase.com). Although current cash is sufficient for the near-term, by 2027 the runway could shrink. The outstanding warrants and preferred shares present a dilution overhang: for example, if the Tranche A $25M warrant is exercised post-approval, it will dilute the equity base (albeit bringing in cash). There’s also a general risk that future financing may occur on unfavorable terms if the stock price is low, which can significantly dilute existing holders (edgar.secdatabase.com). Past financing rounds in 2023 and 2024 dramatically increased the share count (UNCY did a 1:10 reverse split to maintain listing compliance), illustrating how dilution has been an ongoing red flag.
- Market and Competition Risk: The phosphate binder market is competitive and filled with well-established competitors. Generic sevelamer, calcium acetate, lanthanum carbonate, and newer options like sucroferric oxyhydroxide (Velphoro) are all vying for use. These are often backed by large pharmaceutical or specialty companies (e.g., generics manufacturers and dialysis service companies). Unicycive, in contrast, will be a small organization. Competitors with bigger financial resources could outcompete on pricing, distribution deals (with dialysis chains), or bundling of products (edgar.secdatabase.com) (edgar.secdatabase.com). If a larger company with a phosphate binder cuts its price or if dialysis providers prefer to stick to a known regimen, OLC could struggle to gain traction. Moreover, Ardelyx’s Xphozah introduction means there’s now an alternative mechanism in the mix; while OLC’s niche is reducing pill burden of binders, Xphozah’s niche is being an add-on to tough cases – it’s possible some physicians might try using Xphozah to reduce the need for high binder doses, indirectly competing with the “reduce pill count” value proposition of OLC. In short, competition and market dynamics pose a risk that OLC’s sales could underwhelm.
- Manufacturing and Supply Risk: It may seem the manufacturing issue was solved, but it’s still a risk area going forward. OLC will be produced by a third-party contract manufacturer. Any lapse in quality compliance or capacity constraints at this vendor could disrupt supply. Recall that the entire approval was delayed due to that vendor’s compliance status (ir.unicycive.com) – this highlights reliance on a partner outside Unicycive’s full control. The company says the vendor has made progress and is inspection-ready (ir.unicycive.com), but until FDA formally clears it (likely via a pre-approval inspection or review of records), there remains a risk. Post-approval, maintaining good manufacturing practices (CGMP) is critical; any future FDA warning letter or compliance problem could lead to product supply halts or even recalls (ir.unicycive.com) (ir.unicycive.com). Such events would harm Unicycive’s reputation and finances.
- Single-Product Concentration: Unicycive’s fate in the coming years is almost entirely tied to one product, OLC. The pipeline asset UNI-494 is too early-stage to provide diversification or backup. If OLC hits a snag – be it regulatory rejection, serious safety issue in post-market use, or commercial failure – there is no other revenue-generating product to cushion the blow. This “all eggs in one basket” risk is common for small biotechs, but it’s a red flag to weigh. The company’s accumulated deficit was ~$101 million as of end 2024 (edgar.secdatabase.com), and it has zero product revenues to date (edgar.secdatabase.com), so the entire investment thesis rests on turning OLC into a commercial success.
- Governance or Strategic Risks: Unicycive’s agreement to pay out 75% of operating cash flow as dividends (if OLC is successful) is unusual, and could potentially strain future resources. While it’s a shareholder-friendly gesture, it may limit funds available for expanding the pipeline or weathering any setbacks, unless the company raises or borrows money to supplement. Additionally, the company’s need to attract and retain talent for commercialization is a soft risk – launching a drug will require experienced sales, medical affairs, etc. in a competitive hiring market. There’s also always the possibility of M&A or partnerships: a larger pharma could see OLC’s potential and attempt to partner or acquire UNCY. Depending on terms, that could be a positive or, if done at a low valuation, a disappointment.
In summary, Unicycive faces the typical high risks of a single-product biotech: regulatory uncertainty, significant commercial execution challenges, and financial/dilution pressures. Investors should be prepared for volatility around key events (FDA inspections, final approval decision, launch metrics) and recognize that, despite management’s optimism, success is not assured. Many of these risks are spelled out in the company’s SEC filings – e.g., the risk of not obtaining approvals or failing to achieve market acceptance (edgar.secdatabase.com) (edgar.secdatabase.com) – and they remain very relevant as we head toward the PDUFA date.
Open Questions & Outlook
As Unicycive approaches mid-2026, several open questions will determine its trajectory:
- Will OLC be approved on time? This is the most immediate question. All signs point to a straightforward review focused on manufacturing fixes, but investors will be eager for any FDA feedback or inspection updates in the coming months. A formal approval by the June 27, 2026 target date would validate the company’s efforts – any delay or unexpected request from FDA would raise concerns.
- Can Unicycive execute a successful launch alone, or will it seek a partner? So far, the company is preparing to launch OLC in the U.S. with its own commercial team (ir.unicycive.com). This is ambitious for a small biotech. We will watch for whether Unicycive builds a nephrology-focused sales force internally, or if it opts for a commercial partnership with a larger pharma or a specialty distributor (e.g., one of the companies that market products to dialysis centers). The fact that Unicycive already partnered OLC in Asia (with Lee’s Pharmaceutical) (edgar.secdatabase.com) shows a willingness to collaborate in certain geographies. An open question is whether a U.S. or Europe partnership might be explored to maximize OLC’s reach, or if management is intent on going it alone domestically to capture full value. Any co-promotion or licensing deal could bring non-dilutive cash and sales infrastructure, but would also split economics.
- How will OLC be priced, and will payors cover it? Pricing strategy is crucial. If OLC is priced at a premium to generic binders, Unicycive will need to demonstrate the pharmacoeconomic benefit of better adherence (for example, fewer hospitalizations from better phosphate control). Will Medicare and private insurers readily add OLC to formularies? Given that dialysis patients are often covered under Medicare ESRD plans, reimbursement and bundling (dialysis clinics sometimes receive bundled payments) could be complex. An open question is whether UNCY might price OLC competitively to drive adoption or position it as a high-value therapy justified by outcomes. Early indications from the Xphozah launch (which likely pursued a specialty pharma pricing model) will be informative. Unicycive might provide guidance on how they intend to navigate reimbursement, but until launch, it’s an uncertainty.
- How big is the true demand for a lower-pill-burden binder? We know qualitatively that pill burden is a major issue – dialysis patients can require 6-9 pills per meal of phosphate binders, leading to compliance problems. OLC’s nanoparticle formula aims to cut that significantly (ir.unicycive.com). An open question is: if given a choice, will patients and doctors switch to OLC in large numbers? In other words, how much better is OLC’s pill burden reduction in real-world use, and will that translate to improved phosphate levels and patient outcomes? If the benefit is clear and substantial, OLC could rapidly gain market share. If it’s modest, physicians might be more indifferent. We’ll look for data on pill burden reduction – perhaps the company will publish or present data on how many OLC pills per day are needed versus sevelamer, etc., to achieve target phosphate levels.
- What is the plan for UNI-494 and the broader pipeline? Once OLC’s fate is known, attention will turn to Unicycive’s pipeline depth. UNI-494’s development has been relatively quiet; it completed Phase 1, but what next? Will Unicycive initiate Phase 2 trials on its own (which would cost money and bandwidth), or seek a partner for this asset? Also, are there other molecules or in-licensing opportunities on the horizon? The open question is whether Unicycive remains a one-product company or can leverage OLC’s success (if achieved) to broaden its portfolio. The dividend policy complicates this – paying out 75% of operating cash flow would leave only 25% for reinvestment, which might slow pipeline growth. Investors might want clarity on how strictly the company will adhere to that policy versus retaining earnings for R&D.
- Could Unicycive become a takeover target? Small biotechs with an approved (or approvable) product in a sizable market often attract interest from larger players. If OLC is approved, will big pharma or a major nephrology player (for instance, Vifor/Fresenius or Sanofi) make a move to acquire Unicycive? The open question for shareholders is whether the company will remain independent or if an exit is possible. Any acquisition would likely hinge on how compelling OLC’s value proposition is perceived (e.g., if it can displace existing therapies). For now, this is speculative, but it’s something to watch post-approval.
Looking ahead, 2026 is poised to be a defining year for Unicycive. The FDA’s acceptance of the OLC NDA resubmission is a big green light signaling that the company is back on track after the manufacturing setback. If all goes well, by mid-year UNCY could have its first approved drug. That would transform the company from a development-stage story into a commercial operation. Investors will be closely monitoring FDA communications, any partnership announcements, and the company’s preparations for launch (hiring of sales leadership, manufacturing scale-up, etc.). Each of those will help answer the open questions above.
In conclusion, UNCY offers a high-risk, high-reward profile at this juncture. The upside – a successful OLC approval and launch – could unlock significant shareholder value given the large patient need and relatively low current valuation. The downside risks, however, are non-trivial: a hiccup in approval or a tough market reception could keep the stock grounded. As always, due diligence and a close eye on news flow are warranted. For now, the FDA’s acceptance of the NDA is an encouraging milestone that brings “big news ahead” – a potential FDA approval decision – squarely into view for mid-2026. Investors should brace for volatility, but also for a pivotal moment in Unicycive’s journey from lab to marketplace.
Sources:
1. Unicycive Therapeutics – FDA Type A Meeting update & NDA resubmission plans (ir.unicycive.com) (ir.unicycive.com) 2. Unicycive Therapeutics – FDA NDA Resubmission Acceptance press release (Jan 29, 2026) (ir.unicycive.com) (ir.unicycive.com) (ir.unicycive.com) (ir.unicycive.com) (ir.unicycive.com) 3. Unicycive Therapeutics 2024 Annual Report (Form 10-K) – Dividend policy, financing and risk disclosures (edgar.secdatabase.com) (edgar.secdatabase.com) (edgar.secdatabase.com) (edgar.secdatabase.com) 4. Unicycive Therapeutics Q3 2025 Report (Form 10-Q) – Balance sheet and financials (www.sec.gov) (www.sec.gov) 5. BioPharma Dive – Ardelyx’s Xphozah approval and launch context (www.biopharmadive.com) (www.biopharmadive.com) 6. Mordor Intelligence – Hyperphosphatemia drugs market size estimate (www.mordorintelligence.com) 7. Unicycive Therapeutics 2024 Annual Report – OLC Asia partnership (Lee’s Pharm) (edgar.secdatabase.com) and additional risk factors (ir.unicycive.com) (ir.unicycive.com) (edgar.secdatabase.com)
